Zentalis Pharmaceuticals (ZNTL) Projected to Post Quarterly Earnings on Wednesday

Zentalis Pharmaceuticals (NASDAQ:ZNTL) is projected to announce its Q4 2025 results before the market opens on Wednesday, March 25th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, April 3, 2026 at 5:00 PM ET.

Zentalis Pharmaceuticals Stock Down 3.4%

Zentalis Pharmaceuticals stock opened at $2.53 on Tuesday. The company has a 50 day moving average of $2.63 and a 200-day moving average of $1.92. Zentalis Pharmaceuticals has a twelve month low of $1.01 and a twelve month high of $3.95. The stock has a market capitalization of $182.79 million, a PE ratio of -1.22 and a beta of 1.71.

Insider Transactions at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, insider Vincent Vultaggio sold 29,951 shares of the firm’s stock in a transaction on Friday, February 6th. The stock was sold at an average price of $2.43, for a total transaction of $72,780.93. Following the transaction, the insider owned 156,779 shares in the company, valued at $380,972.97. This trade represents a 16.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Group Walters acquired 6,459,973 shares of the company’s stock in a transaction on Wednesday, December 31st. The stock was bought at an average cost of $1.20 per share, with a total value of $7,751,967.60. Following the completion of the acquisition, the insider directly owned 13,509,973 shares in the company, valued at approximately $16,211,967.60. This represents a 91.63% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have sold 46,617 shares of company stock worth $113,417. 1.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Millennium Management LLC raised its position in Zentalis Pharmaceuticals by 220.6% in the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock valued at $4,881,000 after purchasing an additional 2,111,951 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Zentalis Pharmaceuticals by 0.7% in the third quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock valued at $4,386,000 after buying an additional 19,768 shares during the period. Renaissance Technologies LLC increased its stake in shares of Zentalis Pharmaceuticals by 24.0% in the fourth quarter. Renaissance Technologies LLC now owns 2,883,745 shares of the company’s stock valued at $3,893,000 after buying an additional 558,390 shares during the period. Bank of America Corp DE raised its holdings in Zentalis Pharmaceuticals by 117.1% in the 3rd quarter. Bank of America Corp DE now owns 1,548,781 shares of the company’s stock valued at $2,339,000 after buying an additional 835,466 shares during the last quarter. Finally, Opaleye Management Inc. boosted its position in Zentalis Pharmaceuticals by 342.6% during the 4th quarter. Opaleye Management Inc. now owns 1,400,906 shares of the company’s stock worth $1,891,000 after buying an additional 1,084,356 shares during the period.

Analysts Set New Price Targets

Separately, Wells Fargo & Company initiated coverage on Zentalis Pharmaceuticals in a research note on Tuesday, March 17th. They set an “equal weight” rating and a $5.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $5.00.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.